Literature DB >> 24553082

Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.

Fei Duan1, Ming Lin1, Chuanyin Li1, Xia Ding1, Guanxiang Qian1, He Zhang1, Shengfang Ge1, Xianqun Fan1, Jin Li1.   

Abstract

UNLABELLED: The Hedgehog (Hh) signaling pathway has been demonstrated to play a critical role in controlling embryonic development, tissue patterning, wound healing and a variety of cell functions. Aberrant activation of Hh signaling is implicated in the pathogenesis of many human cancers, and in angiogenesis. However, the role of this pathway in uveal melanoma (UM) carcinogenesis remains unknown. In this study, we investigated the effects of Hh inhibition using the specific Smoothened (Smo) antagonist cyclopamine to block Hh signaling in cultured human UM cell lines expressing Hh signaling components. Cyclopamine treatment effectively increased apoptosis and inhibited cell proliferation, migration, and epithelial-to-mesenchymal transition (EMT) by downregulating the Hh final arbiter glioblastoma 1 (Gli1), which regulates the transcription of target genes in the nucleus. Changes in gene and protein expression levels were detected by real-time PCR and by western blotting and immunocytochemistry, respectively. Cell cycle and apoptosis regulation induced by cyclopamine were demonstrated by flow cytometry. In addition, the migration capability of UM cells was reduced, as demonstrated by transwell migration and scratch assays. The effects of Hh inhibition on the levels of angiogenesis factors secreted by UM cells were examined by tube-formation assay.
CONCLUSION: Blocking the Hh pathway by cyclopamine decreased cell viability, migration, EMT, and angiogenesis, increased apoptosis, and induced G 1 phase cell cycle arrest in UM cells. Collectively, these results provide the first evidence of the significance of Gli1 activation downstream of Smo as a therapeutic target and the potential value of cyclopamine for the treatment of human UM.

Entities:  

Keywords:  Hedgehog signaling pathway; cell growth; cell migration; cyclopamine; uveal melanoma

Mesh:

Substances:

Year:  2014        PMID: 24553082      PMCID: PMC4026077          DOI: 10.4161/cbt.28157

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  63 in total

Review 1.  Activation of the hedgehog-signaling pathway in human cancer and the clinical implications.

Authors:  L Yang; G Xie; Q Fan; J Xie
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

Review 2.  Epithelial-mesenchymal transition in cancer development and its clinical significance.

Authors:  Masaaki Iwatsuki; Koshi Mimori; Takehiko Yokobori; Hideshi Ishi; Toru Beppu; Shoji Nakamori; Hideo Baba; Masaki Mori
Journal:  Cancer Sci       Date:  2009-10-28       Impact factor: 6.716

Review 3.  Uveal melanoma: trends in incidence, treatment, and survival.

Authors:  Arun D Singh; Mary E Turell; Allan K Topham
Journal:  Ophthalmology       Date:  2011-06-24       Impact factor: 12.079

4.  Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.

Authors:  Adam Steg; Hope M Amm; Zdenek Novak; Andra R Frost; Martin R Johnson
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

5.  Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma.

Authors:  Yixiong Zhou; Xin Song; Renbin Jia; Haibo Wang; Liyan Dai; Xiaofang Xu; Ping Gu; Shengfang Ge; Xianqun Fan
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-13       Impact factor: 4.693

6.  A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors.

Authors:  Kah Jing Lim; Savita Bisht; Eli E Bar; Anirban Maitra; Charles G Eberhart
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

7.  Hedgehog signaling drives cellular survival in human colon carcinoma cells.

Authors:  Tapati Mazumdar; Jennifer DeVecchio; Ting Shi; Janay Jones; Akwasi Agyeman; Janet A Houghton
Journal:  Cancer Res       Date:  2010-12-06       Impact factor: 12.701

8.  β-catenin and Gli1 are prognostic markers in glioblastoma.

Authors:  Marco Rossi; Letizia Magnoni; Clelia Miracco; Elisa Mori; Piero Tosi; Luigi Pirtoli; Paolo Tini; Giuseppe Oliveri; Elena Cosci; Annette Bakker
Journal:  Cancer Biol Ther       Date:  2011-04-15       Impact factor: 4.742

9.  GLI2-mediated melanoma invasion and metastasis.

Authors:  Vasileia-Ismini Alexaki; Delphine Javelaud; Leon C L Van Kempen; Khalid S Mohammad; Sylviane Dennler; Flavie Luciani; Keith S Hoek; Patricia Juàrez; James S Goydos; Pierrick J Fournier; Claire Sibon; Corine Bertolotto; Franck Verrecchia; Simon Saule; Veronique Delmas; Robert Ballotti; Lionel Larue; Philippe Saiag; Theresa A Guise; Alain Mauviel
Journal:  J Natl Cancer Inst       Date:  2010-07-21       Impact factor: 13.506

10.  Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II.

Authors:  He Zhang; Beibei Niu; Ji-Fan Hu; Shengfang Ge; Haibo Wang; Tao Li; Jianqun Ling; Brandon N Steelman; Guanxiang Qian; Andrew R Hoffman
Journal:  J Cell Biol       Date:  2011-05-02       Impact factor: 10.539

View more
  3 in total

1.  Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82.

Authors:  Qing-Hui Zhang; Yong-Liang Yao; Xiao-Yang Wu; Jian-Hong Wu; Tao Gu; Ling Chen; Jin-Hua Gu; Yun Liu; Ling Xu
Journal:  Dig Dis Sci       Date:  2015-02-05       Impact factor: 3.199

2.  The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.

Authors:  Jianjun Bi; Peng Li; Chuanyin Li; Jie He; Ying Wang; He Zhang; Xianqun Fan; Renbing Jia; Shengfang Ge
Journal:  Tumour Biol       Date:  2015-10-22

Review 3.  Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance.

Authors:  Komaraiah Palle; Chinnadurai Mani; Kaushlendra Tripathi; Mohammad Athar
Journal:  Cancers (Basel)       Date:  2015-11-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.